{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-005702","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.531680+00:00","generated_at":"2026-05-16T03:58:54.625981+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation","bullets":["12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.","No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).","Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.","Three patients remain alive at 15, 14, and 8 months post-treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-005702","json":"https://secwatch.observer/filing/0001493152-26-005702.json","markdown":"https://secwatch.observer/filing/0001493152-26-005702.md","text":"https://secwatch.observer/filing/0001493152-26-005702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/0001493152-26-005702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:58:54.625981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}